QCG
BTAI icon

Quadrant Capital Group’s BioXcel Therapeutics BTAI Stock Holding History

Quadrant Capital Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-53
Closed -$15.8K – 2700
2023
Q1 		$15.8K Buy
+53
New +$22.6K ﹤0.01% 1816
2022
Q4 		– Sell
-8
Closed -$2K – 2748
2022
Q3 		$2K Buy
+8
New +$1.86K ﹤0.01% 2344

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Quadrant Capital Group's BTAI Position: Q2 2023 in Review

Quadrant Capital Group sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 53 shares — an estimated $15.8K sold.

Quadrant Capital Group first reported a position in BTAI in Q3 2022 and held it in 2 quarters. The position peaked at $15.8K in Q1 2023. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

  • Quadrant Capital Group reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 53 BioXcel Therapeutics shares in Q2 2023, an estimated $15.8K.
  • Quadrant Capital Group first reported a position in BioXcel Therapeutics in Q3 2022 and held it in 2 quarters.
  • Quadrant Capital Group's BioXcel Therapeutics position peaked at $15.8K in Q1 2023.
  • 88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.